• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Vascular Solutions CEO’s reputation precedes him

Vascular Solutions CEO’s reputation precedes him

May 7, 2010 By MedCity News

MedCity News logo

Thomas Lee

Howard Root wants you to know that he’s not an angry man. Really.

Yes, the CEO of Vascular Solutions Inc. (NSDQ:VASC) sued another company for product defamation (Vascular won $3.5 million), tangled with local reporters (not me, at least not yet), and threatened not to develop any new products with Minnesota doctors if the state passed a disclosure bill (the legislation died).

And yes, he says what he thinks (Root was a debater at University of Minnesota law school).

“You get put into a position when you come across as hostile,” Root said. “People think I yell when I use the same tone because the point is sharp. A lot of people in medical devices think that. I do get beat up for it.”

But Vascular has emerged in recent years as a successful maker of peripheral and coronary artery devices precisely because Root has shied away from confrontation. Almost obliterated by head-to-head competition with St. Jude Medical Inc. (NYSE:STJ) in 2001, the company shifted gears and introduced multiple “small” products in niche markets largely ignored by the big medical device manufacturers.

Last month, Vascular said its first-quarter revenue jumped 15 percent, to an all-time high of $18.2 million, compared to $15.8 million during the same period last year. Excluding the $3.5 million from the defamation lawsuit, profits grew 35 percent, to $1.27 million. Gross profit margins across all products lines was a whopping 66.7 percent.

“The company has a nice, profitable strategy,” said Ernest Andberg, an equity analyst with Feltl & Co. in Minneapolis. Out of all the emerging medical device companies he covers, Andberg said, Vascular displays the most consistent growth and profitability.

The company closed May 6 at $10.10 a share, about 47 percent higher than at this point in 2009. Andberg even thinks investors are undervaluing Vascular by a dollar or two a share.

Armed with $22.4 million in cash, Vascular is now looking to expand through acquisitions: Earlier this week, it paid $5.75 million to acquire two ultrasound-guided needle products from from Escalon Vascular Access Inc., a division of Escalon Medical Corp. (NSDQ:ESMC).

That the Vascular of today is shopping for assets is remarkable when you consider the company was on the verge of extinction nearly a decade ago. Back then the firm, which went public in 2000, was selling only one product: The Duett, a sealing device that stopped bleeding of the femoral artery during surgery. A year later, St. Jude acquired similar technology from Tyco and quickly grabbed 85 percent market share.

Root said the company faced a critical decision.

“We were locked into a minority [market] position,” he said. “I got one shot to make it. I couldn’t wait until we had the money.”

So the company expanded its portfolio by developing many products in small markets, such as varicose veins, bio-based anti-clotting devices and a variety of catheters, micro-inducer kits, snares and specialty guidewires. Vascular also targeted doctors like pediatric interventional cardiologists, even though there are only 100 such physicians in the world, Root said.

“The big companies will not do it,” he said. “You don’t pick a fight with a bruiser the first day of school. Better yet, pick a place where you don’t get beat up.”

Last November, Vascular launched its GuideLiner catheters, designed to help surgeons with deep intubations during procedures to unclog coronary arteries. The company also hopes to fix its Acolysis ultrasound thrombolysis system, which uses low frequency, high energy ultrasound to remove blood clots. Vascular paid $2 million for the technology in 2002 but technical problems hobbled the product, which is not yet approved for use in the U.S.

Root said Vascular has reached a point where it needs acquisitions to boost growth.

“We’re great innovators on products that won’t make us a lot of money,” Root said. “We do have to step up on scale.”

Vascular is looking for $5 million, $10 million, $20 million deals to acquire “orphans” — market-ready products neglected by other companies that need better sales and marketing. One of Root’s proudest feats is building a dedicated sales force.

“Having a dedicated sales force is huge,” Root said. “We get most of our ideas from 80 sales reps making 2,000 calls a week than consulting with doctors. The direct sales force is the only way I can get direct access” to customers.

Feltl’s Andberg said the orphan strategy makes sense in the short term, as long as the company generates enough cash to finance the deals. Vascular could get tied down with lawsuits, especially intellectual property disputes, he said.

Andberg would also like to see a succession plan at Vascular, since so much of the company’s fortunes rest with its CEO and founder. That could be a challenge, giving Root’s outsized, polarizing personality.

“People either love working for me or hate working for me,” Root said.

Filed Under: Business/Financial News, News Well Tagged With: vascularsolutions

In case you missed it

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance

RSS From Medical Design & Outsourcing

  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy